AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT01144572
- Locations
- 🇨🇳
Research Site, Wenzhou, Zhejiang, China
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14752
- Registration Number
- NCT01144338
- Locations
- 🇬🇧
Research Site, West Sussex, United Kingdom
Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 487
- Registration Number
- NCT01140542
A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients
Completed
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 136
- Registration Number
- NCT01139619
- Locations
- 🇸🇪
Research Site, Lulea, Sweden
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2996
- Registration Number
- NCT01137474
- Locations
- 🇺🇸
Arcuri Clinical Research Llc, Philadelphia, Pennsylvania, United States
🇺🇸Philadelphia Health Associates - Adult Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Cedar Crosse Research Center, Chicago, Illinois, United States
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: 80/2.25 μg Symbicort pMDIDrug: 80/4.5 μg Symbicort pMDIDrug: placebo HFA pMDI
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT01136655
- Locations
- 🇿🇦
Research Site, Dublin, South Africa
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 304
- Registration Number
- NCT01136382
- Locations
- 🇿🇦
Research Site, Panorama, W Cape, South Africa
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT01135446
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease
Completed
- Conditions
- GERD
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01134367
- Locations
- 🇷🇸
Research Site, Zrenjanin, Serbia
A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT01130909
- Locations
- 🇫🇷
Research Site, Rouffach, France